Pfizer’s breakthrough anticancer drug Sunitinib Malate, which got marketing approval in January 26, 2006 by the Food and Drug Administration for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) has been a subject of pending mail-box Application No IN/PCT/2002/00785/DEL (the Application) filed at Delhi Patent Office. Marketed as Sutent, Sunitinib has worldwide sales of US $ 219 million in the first year of its marketing launch (source: Pfizer Annual Report 2006). The Application is filed on August 09, 2002 and subsequently published by the Patent Office on January 19, 2007 claiming earliest priority from US provisional application No. 60/182,710 filed February 15, 2000 against which Orange Book listed US Patent No. 6,573,293 and 7,125,905 are issued on June 03, 2003 and October 24, 2006 respectively.